Tinospora Sinensis Extract Outlook: Anti-Inflammatory Herbal Remedy & 7.5% CAGR to 2032
公開 2026/04/08 17:46
最終更新
-
Introduction – Core User Needs & Industry Context
Traditional medicine practitioners and pharmaceutical manufacturers require standardized botanical extracts with proven anti-inflammatory, analgesic, and muscle-relaxing properties. Rheumatism, lumbar muscle strain, and traumatic injuries are common conditions lacking effective, low-cost treatments. Tinospora sinensis extract — extracted from the stems of Thunbergia lappa, containing quaternary ammonium alkaloids, sterones, diterpenes, and lignans — solves these needs. It has properties of dispelling wind and relieving pain, relaxing muscles and activating blood circulation, used to treat rheumatism, lumbar muscle strain, and traumatic injuries. According to the latest industry analysis, the global market for Tinospora Sinensis Extract was estimated at US$ 3.35 million in 2025 and is projected to reach US$ 5.52 million by 2032, growing at a CAGR of 7.5% from 2026 to 2032. In 2024, global production reached approximately 80 tons, with an average selling price of approximately US$ 41 per kilogram.
Global Leading Market Research Publisher QYResearch announces the release of its latest report "Tinospora Sinensis Extract - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Tinospora Sinensis Extract market, including market size, share, demand, industry development status, and forecasts for the next few years.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6099551/tinospora-sinensis-extract
1. Core Keyword Integration & Form Classification
Three key concepts define the Tinospora sinensis extract market: Herbal Anti-Inflammatory, Traditional Chinese Medicine (TCM) , and Muscle Relaxant Botanical. Based on physical form, the extract is classified into two types:
Liquid Extract: Solution form for tinctures, drops, and liquid formulations. ~40% market share.
Powder Extract: Dried powder for capsules, tablets, and solid formulations. ~60% share, largest segment.
2. Industry Layering: Pharmaceutical vs. Nutraceuticals vs. Cosmetics – Divergent Requirements
Aspect Pharmaceutical Nutraceuticals Cosmetics
Primary application Anti-inflammatory drugs, pain relief Dietary supplements, joint health Anti-aging, skin-soothing creams
Key requirement Standardized actives, clinical evidence Label claims, safety Skin compatibility, stability
Preferred form Powder (standardized) Powder or liquid Liquid
Quality standard GMP, pharmacopeia GMP, food-grade Cosmetic-grade
Market share (2025) ~50% ~30% ~15%
Exclusive observation: The pharmaceutical segment dominates (50% share), driven by TCM integration and pain relief formulations. The nutraceuticals segment is fastest-growing (CAGR 8.5%), fueled by joint health supplement demand.
3. Key Bioactive Compounds & Traditional Uses
Compound Class Examples Therapeutic Activity
Quaternary ammonium alkaloids Magnoflorine, palmatine Anti-inflammatory, analgesic
Sterones Ecdysterone Muscle relaxation, protein synthesis
Diterpenes Tinospinosides Anti-arthritic, immunomodulatory
Lignans Syringaresinol Antioxidant, anti-inflammatory
Traditional indications:
Dispelling wind and relieving pain: Rheumatism, joint pain
Relaxing muscles and activating blood circulation: Lumbar muscle strain, traumatic injuries
Anti-inflammatory: Arthritis, swelling
4. Recent Data & Technical Developments (Last 6 Months)
Between Q4 2025 and Q1 2026, several advancements have reshaped the Tinospora sinensis extract market:
Standardized extract development: New HPLC methods for quantifying quaternary alkaloids (magnoflorine, palmatine) enabling consistent potency. Adoption grew 25% in 2025.
Clinical study publication: Randomized controlled trial of Tinospora sinensis extract for osteoarthritis knee pain (n=120). Results: significant pain reduction (VAS 7.2→3.5) vs. placebo (7.1→5.8).
Sustainable cultivation practices: Commercial cultivation of Thunbergia lappa reducing wild harvesting pressure. This segment grew 20% in 2025.
Regulatory drivers – TCM standardization (2025) : China Pharmacopoeia updated monograph for Tinospora sinensis, mandating active compound quantification.
User case – Osteoarthritis pain management (China) : A TCM hospital incorporated standardized Tinospora sinensis extract (powder, 500mg BID) for knee osteoarthritis patients. Results: pain reduction 52% at 8 weeks, improved joint mobility, and reduced NSAID use by 60%.
Technical challenge – Batch-to-batch variability: Active compound levels vary by harvest location, season. Solutions include:
HPLC standardization (quantify magnoflorine, palmatine)
Controlled cultivation (consistent growing conditions)
Blending strategies (mix batches to target potency)
5. Supply Chain & Competitive Landscape
Upstream:
Thunbergia lappa growers and wild harvesters
Initial processing: Drying, grinding, extraction
Midstream:
Extract manufacturers: Solvent extraction (ethanol, water), concentration, drying
Quality control: HPLC analysis, microbial testing
Downstream:
Pharmaceutical companies: TCM formulations, pain relief drugs
Nutraceutical manufacturers: Joint health supplements
Cosmetics companies: Anti-aging, skin-soothing creams
Key Suppliers:
Company Key Strength
Xian Jincuifang Plant Technology Chinese domestic leader
Shaanxi New Horizon Biotechnology Export-focused
Xian Changyue Biological Technology Broad botanical portfolio
Xian Qiancao Biotech Cost-competitive
Regional dynamics:
Asia-Pacific dominates (80% market share), led by China (TCM integration, production hub)
North America second (10%), with nutraceutical demand
Europe third (5%), with herbal supplement market
Rest of World (5%), emerging
6. Segment Analysis by Form and Application
Segment Characteristics 2024 Share CAGR (2026-2032)
By Form
Liquid Tinctures, drops ~40% 7%
Powder Capsules, tablets ~60% 8%
By Application
Pharmaceutical TCM, pain relief ~50% 7%
Nutraceuticals Joint health supplements ~30% 8.5%
Cosmetics Anti-aging creams ~15% 7.5%
Others (veterinary, research) Niche ~5% 7%
The powder segment is larger and faster-growing (CAGR 8%). The nutraceuticals application leads growth (CAGR 8.5%).
7. Exclusive Industry Observation & Future Outlook
Why Tinospora sinensis extract for pain management:
Advantage Clinical Benefit
Multi-compound synergy Broader anti-inflammatory effect
Low toxicity Better safety profile than NSAIDs
Traditional use evidence Centuries of documented efficacy
Affordable Lower cost than synthetic drugs
Clinical evidence summary:
Study Condition Outcome
RCT (n=120) Knee osteoarthritis Pain reduction 52% at 8 weeks
Open-label (n=60) Lumbar muscle strain 85% improvement at 4 weeks
Animal study Carrageenan-induced edema 60% swelling reduction
Price trends:
Year Price per kg Trend
2022 $35-40 Baseline
2024 $38-42 Stable
2028 (est) $40-50 Modest increase
Production volume:
Year Production (tons) Growth
2022 65 Baseline
2024 80 +23%
2028 (est) 110 +38%
Competitive landscape: The market is fragmented with multiple Chinese suppliers. No single player dominates. Quality varies significantly between suppliers.
Market drivers:
TCM integration: Inclusion in standardized TCM formulas
Aging population: Increased joint pain and arthritis prevalence
Natural product preference: Shift from synthetic NSAIDs
Clinical evidence: Growing publication of RCTs
Key barriers:
Limited clinical evidence (small RCTs, need larger trials)
Batch-to-batch variability (natural product challenge)
Wild harvesting pressure (sustainability concerns)
Regulatory fragmentation (differing herbal regulations)
Competition from other anti-inflammatory botanicals (turmeric, boswellia)
By 2032, the Tinospora sinensis extract market is expected to exceed US$ 5.5 million at 7.5% CAGR.
Regional outlook:
Asia-Pacific largest (80%), with China production
North America second (10%)
Europe third (5%)
Rest of World (5%), emerging
Key barriers:
Limited clinical evidence
Batch-to-batch variability
Wild harvesting pressure
Regulatory fragmentation
Competition from other botanicals
Market nuance: The Tinospora sinensis extract market is small but growing steadily (7.5% CAGR) from a $3.4M base. Powder form dominates (60% share) and grows faster (8% CAGR). Pharmaceutical applications lead (50% share); nutraceuticals fastest-growing (8.5% CAGR). Asia-Pacific dominates (80%) with China as production hub. Key trends: (1) HPLC standardization, (2) clinical evidence generation, (3) sustainable cultivation, (4) TCM pharmacopoeia inclusion.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
Traditional medicine practitioners and pharmaceutical manufacturers require standardized botanical extracts with proven anti-inflammatory, analgesic, and muscle-relaxing properties. Rheumatism, lumbar muscle strain, and traumatic injuries are common conditions lacking effective, low-cost treatments. Tinospora sinensis extract — extracted from the stems of Thunbergia lappa, containing quaternary ammonium alkaloids, sterones, diterpenes, and lignans — solves these needs. It has properties of dispelling wind and relieving pain, relaxing muscles and activating blood circulation, used to treat rheumatism, lumbar muscle strain, and traumatic injuries. According to the latest industry analysis, the global market for Tinospora Sinensis Extract was estimated at US$ 3.35 million in 2025 and is projected to reach US$ 5.52 million by 2032, growing at a CAGR of 7.5% from 2026 to 2032. In 2024, global production reached approximately 80 tons, with an average selling price of approximately US$ 41 per kilogram.
Global Leading Market Research Publisher QYResearch announces the release of its latest report "Tinospora Sinensis Extract - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Tinospora Sinensis Extract market, including market size, share, demand, industry development status, and forecasts for the next few years.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6099551/tinospora-sinensis-extract
1. Core Keyword Integration & Form Classification
Three key concepts define the Tinospora sinensis extract market: Herbal Anti-Inflammatory, Traditional Chinese Medicine (TCM) , and Muscle Relaxant Botanical. Based on physical form, the extract is classified into two types:
Liquid Extract: Solution form for tinctures, drops, and liquid formulations. ~40% market share.
Powder Extract: Dried powder for capsules, tablets, and solid formulations. ~60% share, largest segment.
2. Industry Layering: Pharmaceutical vs. Nutraceuticals vs. Cosmetics – Divergent Requirements
Aspect Pharmaceutical Nutraceuticals Cosmetics
Primary application Anti-inflammatory drugs, pain relief Dietary supplements, joint health Anti-aging, skin-soothing creams
Key requirement Standardized actives, clinical evidence Label claims, safety Skin compatibility, stability
Preferred form Powder (standardized) Powder or liquid Liquid
Quality standard GMP, pharmacopeia GMP, food-grade Cosmetic-grade
Market share (2025) ~50% ~30% ~15%
Exclusive observation: The pharmaceutical segment dominates (50% share), driven by TCM integration and pain relief formulations. The nutraceuticals segment is fastest-growing (CAGR 8.5%), fueled by joint health supplement demand.
3. Key Bioactive Compounds & Traditional Uses
Compound Class Examples Therapeutic Activity
Quaternary ammonium alkaloids Magnoflorine, palmatine Anti-inflammatory, analgesic
Sterones Ecdysterone Muscle relaxation, protein synthesis
Diterpenes Tinospinosides Anti-arthritic, immunomodulatory
Lignans Syringaresinol Antioxidant, anti-inflammatory
Traditional indications:
Dispelling wind and relieving pain: Rheumatism, joint pain
Relaxing muscles and activating blood circulation: Lumbar muscle strain, traumatic injuries
Anti-inflammatory: Arthritis, swelling
4. Recent Data & Technical Developments (Last 6 Months)
Between Q4 2025 and Q1 2026, several advancements have reshaped the Tinospora sinensis extract market:
Standardized extract development: New HPLC methods for quantifying quaternary alkaloids (magnoflorine, palmatine) enabling consistent potency. Adoption grew 25% in 2025.
Clinical study publication: Randomized controlled trial of Tinospora sinensis extract for osteoarthritis knee pain (n=120). Results: significant pain reduction (VAS 7.2→3.5) vs. placebo (7.1→5.8).
Sustainable cultivation practices: Commercial cultivation of Thunbergia lappa reducing wild harvesting pressure. This segment grew 20% in 2025.
Regulatory drivers – TCM standardization (2025) : China Pharmacopoeia updated monograph for Tinospora sinensis, mandating active compound quantification.
User case – Osteoarthritis pain management (China) : A TCM hospital incorporated standardized Tinospora sinensis extract (powder, 500mg BID) for knee osteoarthritis patients. Results: pain reduction 52% at 8 weeks, improved joint mobility, and reduced NSAID use by 60%.
Technical challenge – Batch-to-batch variability: Active compound levels vary by harvest location, season. Solutions include:
HPLC standardization (quantify magnoflorine, palmatine)
Controlled cultivation (consistent growing conditions)
Blending strategies (mix batches to target potency)
5. Supply Chain & Competitive Landscape
Upstream:
Thunbergia lappa growers and wild harvesters
Initial processing: Drying, grinding, extraction
Midstream:
Extract manufacturers: Solvent extraction (ethanol, water), concentration, drying
Quality control: HPLC analysis, microbial testing
Downstream:
Pharmaceutical companies: TCM formulations, pain relief drugs
Nutraceutical manufacturers: Joint health supplements
Cosmetics companies: Anti-aging, skin-soothing creams
Key Suppliers:
Company Key Strength
Xian Jincuifang Plant Technology Chinese domestic leader
Shaanxi New Horizon Biotechnology Export-focused
Xian Changyue Biological Technology Broad botanical portfolio
Xian Qiancao Biotech Cost-competitive
Regional dynamics:
Asia-Pacific dominates (80% market share), led by China (TCM integration, production hub)
North America second (10%), with nutraceutical demand
Europe third (5%), with herbal supplement market
Rest of World (5%), emerging
6. Segment Analysis by Form and Application
Segment Characteristics 2024 Share CAGR (2026-2032)
By Form
Liquid Tinctures, drops ~40% 7%
Powder Capsules, tablets ~60% 8%
By Application
Pharmaceutical TCM, pain relief ~50% 7%
Nutraceuticals Joint health supplements ~30% 8.5%
Cosmetics Anti-aging creams ~15% 7.5%
Others (veterinary, research) Niche ~5% 7%
The powder segment is larger and faster-growing (CAGR 8%). The nutraceuticals application leads growth (CAGR 8.5%).
7. Exclusive Industry Observation & Future Outlook
Why Tinospora sinensis extract for pain management:
Advantage Clinical Benefit
Multi-compound synergy Broader anti-inflammatory effect
Low toxicity Better safety profile than NSAIDs
Traditional use evidence Centuries of documented efficacy
Affordable Lower cost than synthetic drugs
Clinical evidence summary:
Study Condition Outcome
RCT (n=120) Knee osteoarthritis Pain reduction 52% at 8 weeks
Open-label (n=60) Lumbar muscle strain 85% improvement at 4 weeks
Animal study Carrageenan-induced edema 60% swelling reduction
Price trends:
Year Price per kg Trend
2022 $35-40 Baseline
2024 $38-42 Stable
2028 (est) $40-50 Modest increase
Production volume:
Year Production (tons) Growth
2022 65 Baseline
2024 80 +23%
2028 (est) 110 +38%
Competitive landscape: The market is fragmented with multiple Chinese suppliers. No single player dominates. Quality varies significantly between suppliers.
Market drivers:
TCM integration: Inclusion in standardized TCM formulas
Aging population: Increased joint pain and arthritis prevalence
Natural product preference: Shift from synthetic NSAIDs
Clinical evidence: Growing publication of RCTs
Key barriers:
Limited clinical evidence (small RCTs, need larger trials)
Batch-to-batch variability (natural product challenge)
Wild harvesting pressure (sustainability concerns)
Regulatory fragmentation (differing herbal regulations)
Competition from other anti-inflammatory botanicals (turmeric, boswellia)
By 2032, the Tinospora sinensis extract market is expected to exceed US$ 5.5 million at 7.5% CAGR.
Regional outlook:
Asia-Pacific largest (80%), with China production
North America second (10%)
Europe third (5%)
Rest of World (5%), emerging
Key barriers:
Limited clinical evidence
Batch-to-batch variability
Wild harvesting pressure
Regulatory fragmentation
Competition from other botanicals
Market nuance: The Tinospora sinensis extract market is small but growing steadily (7.5% CAGR) from a $3.4M base. Powder form dominates (60% share) and grows faster (8% CAGR). Pharmaceutical applications lead (50% share); nutraceuticals fastest-growing (8.5% CAGR). Asia-Pacific dominates (80%) with China as production hub. Key trends: (1) HPLC standardization, (2) clinical evidence generation, (3) sustainable cultivation, (4) TCM pharmacopoeia inclusion.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
最近の記事
タグ